55041-27-5

Upstream product

• 95-48-7 ortho-cresol 
• 96-22-0 pentan-3-one 

Downstream Products

• 882041-77-2 trifluoro-methanesulfonic acid 4-[1-ethyl-1-(3-methyl-4-trifluoromethanesulfonyloxy-phenyl)-propyl]-2-methyl-phenyl ester 
• 863408-16-6 4-[3-(4-amino-3-methylphenyl)pentan-3-yl]-2-methylphenol 
• 898253-48-0 4-(1-{4-[3-(2,6-dichloro-phenyl)-5-isopropyl-isoxazol-4-ylmethoxy]-3-methyl-phenyl}-1-ethyl-propyl)-2-methyl-phenol 
• 942194-55-0 4-[1-(4-amino-phenyl)-1-ethyl-propyl]-2-methyl-phenol 
• 2362-14-3 4,4'-cyclohexylidenedi-o-cresol 
• 700832-42-4 4-(3-(4-(benzyloxy)-3-methylphenyl)pentan-3-yl)-2-methylphenol 
• 850917-91-8 4-{1-[4-(tert-butyl-dimethylsilyloxy)-3-methylphenyl]-1-ethylpropyl}-2-methylphenol 
• 233268-82-1 1-(4-(3-(4-hydroxy-3-methylphenyl)pentan-3-yl)-2-methylphenoxy)-3,3-dimethylbutan-2-one 
• 865239-03-8 4-{1-[4-((R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)-3-methyl-phenyl]-1-ethyl-propyl}-2-methyl-phenol 
• 917023-65-5 (4'-{1-[4-(3,3-dimethyl-2-oxo-butoxy)-3-methyl-phenyl]-1-ethyl-propyl}-3-fluoro-2'-methylbiphenyl-4-yl)-acetic acid 
• 917024-87-4 trifluoromethanesulfonic acid 4-{1-ethyl-1-[4-(1-hydroxy-cyclopentylethynyl)-3-methyl-phenyl]-propyl}-2-methyl-phenyl ester 
• 917022-95-8 1-(4-{1-ethyl-1-[3-methyl-4-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-2-yl)-phenyl]-propyl}-2-methyl-phenylethynyl)-cyclopentanol 
• 917022-97-0 1-[2-(4-{1-ethyl-1-[3-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-propyl}-2-methyl-phenyl)-ethyl]-cyclopentanol 
• 917023-43-9 [6-(4-{1-ethyl-1-[4-((E)-3-ethyl-3-hydroxy-1-pentenyl)-3-methyl-phenyl]-propyl}-2-methyl-phenyl)-pyridin-3-yl]-acetic acid 

Relevant academic research and scientific papers

Structure-activity relationships of bisphenol a analogs at estrogen receptors (ERs): Discovery of an ERα-selective antagonist

Our multi-template approach for drug discovery, focusing on protein targets with similar fold structures, has yielded lead compounds for various targets. We have also shown that a diphenylmethane skeleton can serve as a surrogate for a steroid skeleton. H

3,3-Diphenylpentane skeleton as a steroid skeleton substitute: Novel inhibitors of human 5α-reductase 1

We designed and synthesized novel type 1 5α-reductase inhibitors by using 3,3-diphenylpentane skeleton as a substitute for the usual steroid skeleton. 4-(3-(4-(N-Methylacetamido)phenyl)pentan-3-yl)phenyl dibenzylcarbamate (11k) is a competitive 5α-reductase inhibitor with the IC50 value of 0.84 μM.

Vesicant treatment with phenyl-phenyl type vitamin d receptor modulators

The present invention relates to a method of treating or preventing damage to human skin cells by chemical vesicants by administering a non-secosteroidal, diphenyl compound with vitamin D receptor (VDR) modulating activity.

VITAMIN D RECEPTOR MODULATORS

The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon- linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for

VITAMIN D RECEPTOR MODULATORS

The present invention relates to novel, non-secosteroidal, sulfonate and sulfonamide functional diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis. X-15439

BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS

The present invention is directed to 1α,25-dihydroxyvitamin D3 mimics which modulate the vitamin D receptor (VDR). The invention is further directed to pharmaceutical compositions and methods for the treatment, prevention or amelioration of one or more sy

VITAMIN D RECEPTOR MODULATORS

The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Affinity labeling of the nuclear vitamin D receptor with nonsteroidal alkylating agents.

Synthesis of an affinity alkylating non steroidal mimic of 1alpha,25-dihydroxyvitamin D(3) and its radiolabeled counterpart is presented. We also report the affinity labeling of the VDR-ligand binding domain (VDR-LBD) with this analogue.

Polycarbonates exhibiting improved heat resistance

Novel heat resistant polycarbonates are provided which are the polymerized reaction products of: (i) a carbonate precursor; and (ii) at least one dihydric phenol selected from dihydric phenols represented by the general formulae STR1 wherein: each R1 is independently selected from halogen radicals, monovalent hydrocarbon radicals, and monovalent hydrocarbonoxy radicals; each R2 is independently selected from halogen radicals, monovalent hydrocarbon radicals, and monovalent hydrocarbonoxy radicals; R4 and R5 are independently selected from monovalent hydrocarbon radicals; R3 is selected from hydrogen and monovalent hydrocarbon radicals, with the proviso that if R3 is a hydrogen radical than at least one of the monovalent hydrocarbon radicals represented by R4 and R5 contains at least two carbon atoms; R7 is selected from hydrogen and monovalent hydrocarbon radicals; R6 is a divalent hydrocarbon radicals; and n and n' are independently selected from whole numbers having a value of from 0 to 4 inclusive.

Process for the preparation of bisphenols

Processes for the preparation of bisphenols from phenols and substituted vicinal glycols, or unsaturated alcohols or substituted dienes resulting in bisphenols represented by the general formula: STR1 wherein: R1 and R2 are independently selected from monovalent hydrocarbon and monovalent hydrocarbonoxy radicals of one to four carbon atoms, or from halogen radicals; R3, R4 and R5 is each a lower alkyl radical, preferably of one to four carbon atoms, aryl radicals, alkaryl radicals, aralkyl radicals, and cycloalkyl radicals, and is the same or different; R5 may also be hydrogen. n and n1 are independently selected from whole numbers having a value of from 0 to 4 inclusive.